Harmony Biosciences Cash Flow Statement
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences free cash flow
In fiscal 2025, Harmony Biosciences generated $348.2 million of operating cash flow and spent $310,000 on capital expenditures. That left free cash flow of $347.9 million, a free-cash-flow margin of 40.1% of revenue. Free cash flow was up 59.1% from the prior year's $218.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | -36.94M | -151.98M |
| Net Income growth (YoY) | +9.07% | +12.91% | -28.99% | +424.52% | — | — | — |
| Depreciation & Amortization | — | 267.00K | 514.00K | 419.00K | 416.00K | 394.00K | 395.00K |
| Stock-Based Compensation | 44.90M | 42.60M | 31.70M | 26.17M | 15.66M | 4.69M | 9.91M |
| Change in Working Capital | 91.82M | -7.32M | 35.03M | -4.11M | -16.49M | -30.23M | 1.02M |
| Operating Cash Flow | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M | -2.98M | -75.44M |
| Capital Expenditures | -310.00K | -1.15M | -312.00K | -172.00K | -298.00K | -2.00K | -149.00K |
| Investing Cash Flow | -39.65M | -67.48M | -46.44M | -141.83M | -100.30M | -2.00M | -127.15M |
| Share Repurchases | — | — | -100.00M | — | — | -167.00K | — |
| Debt Issued | — | — | 200.00M | — | 200.00M | 200.00M | 100.00M |
| Debt Repaid | -16.25M | -15.00M | -4.75M | -2.00M | -500.00K | — | — |
| Financing Cash Flow | -9.05M | -11.00M | -105.55M | 6.84M | 7.42M | 209.16M | 143.77M |
| Net Change in Cash | 299.50M | 141.34M | 67.40M | 9.47M | 5.68M | 204.17M | -58.82M |
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M | -2.99M | -75.58M |
This table shows 7 annual periods of Harmony Biosciences's cash flow statement, from FY 2025 back to FY 2019, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HRMY's reporting calendar. What is a cash flow statement?